Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway

Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway

Abstract Background Cardiovascular and renal complications of type 2 diabetes are the main causes of death in diabetic patients. Clinical studies have found that polyethylene glycol loxenatide (PEG-Loxe), a GLP-1 analog widely used to treat type 2 diabetes, boosts renal and cardiac functions in diab...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Shi, Qilin Zhang, Yufeng Li, Junjun Zhao, Cong Wang, Yu Zhang
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Cardiovascular Disorders
Subjects:
Polyethylene glycol loxenatide
Type 2 diabetes
Renal injury
Cardiac injury
Endoplasmic reticulum stress
Inflammatory pathway
Online Access:https://doi.org/10.1186/s12872-024-04427-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12872-024-04427-4

Similar Items